Article

Florida Cancer Specialists Researcher Co-Authored SABCS Breast Cancer Study

A member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS) served as co-author of a study presented at San Antonio Breast Cancer Symposium.

Fort Myers, Florida — Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as co-author of a study shared in a poster presentation at the San Antonio Breast Cancer Symposium, which was held December 7-12, 2021.

Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study's analysis indicates a correlation between the TP53 gene and tumor volume following treatment with niraparib over time.

“Mutations in TP53 occur in 30% to 35% of invasive primary breast cancer cases and may be an effective biomarker. Nuraparib, a poly(ADP-ribose) polymerase (PARP)-1/2 inhibitor, provides a new, effective treatment option for BRCA 1/2-mutated early-stage breast cancer after chemotherapy,” said Dr Reeves and fellow researchers.

Learn more.

Related Videos
John Michael O'Brien, PharmD, MPH
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Andrew Kuykendall, MD
AMCP Recap 2025
Andrew Evens, DO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo